Indomethacin Injection

[22 October 2014]

Products Affected - Description

Indomethacin sodium trihydrate lyophilized powder for injection (Indocin I.V.) single-dose vials, package of 3 (NDC 67386-0511-51), Lundbeck Inc. - discontinued1  

Indomethacin sodium lyophilized powder for injection
single-dose vials, package of 1 (NDC 55390-0299-01), West-Ward (formerly Bedford product)2

Reason for the Shortage

  • Indomethacin for injection was on nationwide back order due to manufacturing issues.1,2
  • Lundbeck sold several products to Recordati in January 2013 including Indocin IV and NeoProfen IV. Recordati is not currently manufacturing Indocin IV but NeoProfen is available.3
  • West-Ward Pharmaceuticals’ parent company, Hikma Pharmaceuticals, acquired indomethacin injection from Bedford in July 2014. West-Ward is not actively marketing indomethacin injection at this time.2
  • Fresenius Kabi (formerly APP) had indomethacin injection on shortage due to increase demand for the product.4

Available Products

Indomethacin sodium lyophilized powder for injection, single-dose vials (NDC 63323-0659-03) Fresenius Kabi (formerly APP)4

Estimated Resupply Dates

All currently marketed indomethacin injection presentations are available.4

    Implications for Patient Care

    Indomethacin for injection is labeled for closing hemodynamically significant patent ductus arteriosus (PDA) in premature infants who weigh between 500-1750 g, when medical management is ineffective after 48 hours and there is clinical evidence of respiratory distress, continuous heart murmur, hyperactive precordium, cardiomegaly, or pulmonary plethora (by chest radiography).5 Although not labeled uses, indomethacin for injection has also been used prophylactically to reduce the occurrence of intraventricular hemorrhage in very low birth weight neonates.6,7

    Alternative Agents & Management

    • Ibuprofen lysine injection (Neoprofen) is labeled for closing hemodynamically significant patent ductus arteriosus (PDA) in premature infants who weigh between 500-1750 g and are no more than 32 weeks gestational age, when medical management is ineffective.8
    • Ibuprofen lysine injection has no effect on the incidence of intraventricular hemorrhage when given as prophylaxis in very low birth weight neonates.6,7
    • There are different formulations of intravenous ibuprofen. Ibuprofen lysine (Neoprofen) is the only product labeled for use in premature infants. Use caution when selecting an intravenous ibuprofen product.


    1. Lundbeck Inc (formerly Ovation Pharmaceuticals) (personal communications). November 24, 25, and 30, 2009; January 4 and 20, February 9 and 19, March 16 and 30, May 5, June 9, July 30, August 12, September 1, October 18, December 16, 2010; February 16, March 22, April 22, May 13, June 16, July 27, August 16, September 20, 2011; January 18, March 12, May 24, August 15, October 10 and 30, November 20, 2012; January 23, March 25, May 22, July 25, August 22, and October 15, 2013.
    2. West-Ward Pharmaceuticals (personal communications). August 5, 2014.
    3. Recordati (personal communications). October 15, December 9, 2013; and February 13, May 14, August 14, and October 20, 2014.
    4. Fresenius Kabi (personal communications). May 5, June 9, and August 12, September 1, October 20, December 17, 2010; February 16, March 16, June 15, July 27, August 16, September 16, 22 and 27, October 4 and 26, November 28, 2011; January 17, March 9, May 23, August 13, October 10, November 20, 2012; January 23, March 19, May 22, and August 1, 22, and 30, October 10, December 6, 2013; and February 11, May 12, August 14, and October 13, 2014. 
    5. Indocin I.V. [product information]. Deerfield, IL: Ovation Pharmaceuticals; 2006.
    6. Sekar, KC and Corff, KE. Treatment of patent ductus arteriosus: indomethacin or ibuprofen? J Perinatol 2008;28:S60-s62.
    7. McCrea HJ, Ment RM. The diagnosis, management, and postnatal prevention of intraventricular hemorrhage in the preterm neonate. Clin Perinatol. 2008 Dec;35(4):777-92.
    8. Neoprofen (ibuprofen lysine injection) product information. Deerfield, IL: Lundbeck Inc; 2009.


    Updated October 22, 2014 by Jane Chandramouli, PharmD, Drug Information Specialist. Created November 24, 2009 by Jane Chandramouli, Pharm.D. Drug Information Specialist. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.


    This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

    « Back to Drug Shortage Product Bulletins

    Advocacy Activity
    Get the latest updates on ASHP's advocacy activity on drug shortages.
    ASHP Product Listing